

# Patient Feedback on OraVerse®

OraVerse®  
(Phentolamine Mesylate) Injection

Patient ID: \_\_\_\_\_

*(Please do not use patient name.)*

Date: \_\_\_\_\_

**Lip numbness** OraVerse injection time \_\_\_\_\_ Numbness end time \_\_\_\_\_ Duration \_\_\_\_\_

**Tongue numbness** OraVerse injection time \_\_\_\_\_ Numbness end time \_\_\_\_\_ Duration \_\_\_\_\_

**Difficulty with smiling, speaking, drinking, or drooling** OraVerse injection time \_\_\_\_\_ Difficulty end time \_\_\_\_\_ Duration \_\_\_\_\_

**Please tell us what you think:** *(Circle Yes or No)*

- |  |     |    |
|--|-----|----|
| 1) Do you feel OraVerse improved your dental experience?             | Yes | No |
| 2) Would you be interested in receiving OraVerse at your next visit? | Yes | No |
| 3) Would you recommend OraVerse to family and friends?               | Yes | No |

Comments: \_\_\_\_\_

## Important Safety Information

Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.

OraVerse is indicated for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 33 lbs.

See full prescribing information online at [www.novalar.com](http://www.novalar.com).